En ensayos clnicos recientes, orforglipron ha demostrado reducciones en la hemoglobina glucosilada (HbA1c) de hasta 1.7% y una prdida de peso corporal de hasta 14.7% en adultos con obesidad, cifras que lo colocan a la par de los tratamientos inyectables ms potentes
Discard a vial if any of the signs below show up, or if it has passed its time limit
Some patients and providers may hesitate to advance to higher doses due to side effects, but remaining at lower doses often results in suboptimal weight loss
While the benefits can be substantial, it's important to approach their use with care, under professional guidance, and as part of a comprehensive approach to health and fitness
Very important and practically oriented paper Nice overview of advantages and limitations A must read for anybody who treats these patients To view or add a comment, sign in GLP-1RAs Show Significant Liver and Metabolic Benefits in MASLD A new systematic review and meta-analysis of 32 randomized controlled trials reveals that GLP-1 receptor agonists (GLP-1RAs) significantly improve liver and metabolic outcomes in patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), far outperforming DPP-4 inhibitors, which showed minimal effects beyond glycemic control
It will not promote weight loss
